Litcius/Paper detail

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy

Grace K. Dy, Dheerendra Prasad, Prasanna Kumar, Kristopher Attwood, Alex A. Adjei

2021Journal of Thoracic Oncology15 citationsDOI

Topics & Concepts

NintedanibMedicinePlaceboInternal medicinePneumonitisCommon Terminology Criteria for Adverse EventsRadiation therapyIdiopathic pulmonary fibrosisAdverse effectRandomized controlled trialGastroenterologyClinical endpointOncologySurgeryLungPathologyAlternative medicineInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisLung Cancer Treatments and MutationsPolyomavirus and related diseases
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy | Litcius